We are investigating Catalyst Pharmaceuticals, Inc. (CPRX) (“Catalyst” or the “Company”) for potential violations of the federal securities laws.
On October 30, 2019, Catalyst issued a press release announcing “top-line results from CMS-001, a Phase 3 study evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in adults and children aged 2 years and above.” The press release advised investors that “[w]hile individual patient improvements were observed in some patient sub-groups, the trial did not meet its primary endpoint of subject global impression (SGI) or the secondary endpoint of muscle function measure (MFM) across all tested subtypes.” On this news, Catalyst’s stock price fell $0.74 per share, or 12.98%, to close at $4.96 per share on October 30, 2019.